Stifel reiterates Alumis stock Buy rating after psoriasis data

Envudeucitinib Phase 3 results showed PASI100 rates of 29%/41% and 28%/40% (week 16/24), supporting the TYK2 IC90 thesis and broadly in line with Takeda's Zasocitinib. Analysts are mostly bullish: Stifel reiterated a Buy with a $44 PT, Raymond James initiated at Strong Buy with a $46 PT, while H.C. Wainwright cut its PT to $25 from $40; ALMS shares have jumped ~340% over the past year and trade at $24.80 (market cap $3.15B). InvestingPro flags the stock as currently overvalued and Stifel notes upcoming 3Q26 SLE data as a key strategic catalyst.

Analysis

The data flow and analyst activity have crystallized a market narrative that next‑gen oral TYK2s can meaningfully encroach on the biologics-dominated psoriasis spend — but the real competition is at the payer contracting layer, not the clinic. Oral agents shift treatment from medical benefit (infused/injected biologics with physician-administered channels) to pharmacy benefit scripts, creating leverage for PBMs and limiting list‑price capture; winning commercialization will depend as much on access playbooks and rebate math as on incremental PASI gains.

Second‑order winners include specialty CDMOs and API suppliers that can scale oral small‑molecule production rapidly; conversely, device/auto‑injector vendors and certain specialty pharmacy service models face downstream volume pressure. From a corporate strategy angle, a differentiated label or a positive secondary‑indication readout materially raises M&A odds — acquirers buy clarity on label expansion more than incremental efficacy percentages.

Key risks are binary: label differentiation denied, unforeseen safety signals, or narrow formulary placement will compress upside quickly; conversely, robust payer uptake and favorable guideline changes could drive rapid market share gains within 12–18 months. Given the stock’s rich multiple, the path to justify current valuation requires both durable commercial access and at least one non‑psoriasis proof point — absent those, downside volatility is the most probable near‑term outcome.

Key Decisions for Investors

• ALMS — tactical long via 12–18 month call spread (buy 12‑month ATM calls, sell 24‑month OTM calls) sized 1–2% portfolio: asymmetric upside if label/access story materializes; capped loss ~premium paid (~100% of premium), target 2–3x payoff if positive commercial traction or add‑on readout.
• ALMS — event‑hedged equity: buy stock (small position 0.5–1% portfolio) and purchase 6–12 month puts at ~20–30% OTM to protect against binary negative readouts or access losses; expected cost ~3–6% of notional, limits tail risk while preserving upside exposure.
• ALMS — short bias for momentum reversal: initiate a discretionary short (size <1% net exposure) with tight stop (20% adverse move) if IV collapses post‑presentation or if sell‑side price targets fail to converge on commercial assumptions; reward is rapid de‑rating toward peers if payers block access.
• Capital reallocation — if reducing ALMS exposure, redeploy into small‑cap winners with demonstrable revenue and cleaner cash flows (e.g., SMCI) for 3–9 month horizon: lower binary risk, higher cash conversion, and better downside protection versus event‑driven biotech exposure.